Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
Anna Wesołowska,1 Joanna Rychtyk,1 Joanna Gdula-Argasińska,2 Katarzyna Górecka,1 Natalia Wilczyńska-Zawal,1 Magdalena Jastrzębska-Więsek,1 Anna Partyka1 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0698d54e34d4401ab7e961b71676cadf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0698d54e34d4401ab7e961b71676cadf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0698d54e34d4401ab7e961b71676cadf2021-12-02T17:49:10ZEffect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats1178-2021https://doaj.org/article/0698d54e34d4401ab7e961b71676cadf2021-06-01T00:00:00Zhttps://www.dovepress.com/effect-of-5-ht6-receptor-ligands-combined-with-haloperidol-or-risperid-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Anna Wesołowska,1 Joanna Rychtyk,1 Joanna Gdula-Argasińska,2 Katarzyna Górecka,1 Natalia Wilczyńska-Zawal,1 Magdalena Jastrzębska-Więsek,1 Anna Partyka1 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland; 2Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, PolandCorrespondence: Anna PartykaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, Kraków, 30-688, PolandTel/Fax +48 126 205 654Email annairena.partyka@uj.edu.plBackground: The presence of depressive and anxiety symptoms in patients with schizophrenia may have an important impact on treatment and compliance. Hence, interventions addressing such comorbidity in schizophrenia should be explored. One target may be a serotonergic 5-HT6 receptor (5-HT6R) since its ligands displayed antidepressant- and anxiolytic-like activities in preclinical experiments.Methods: Acute and chronic (21 days) administration of haloperidol or risperidone in combination with a selective 5-HT6R agonist (WAY-181187) or antagonist (SB-742457) to rats was performed for detecting antidepressant- and anxiolytic-like behaviors. In addition, the level of brain-derived neurotrophic factor (BDNF) protein and its gene expression in hippocampus and prefrontal cortex were determined.Results: Both single and chronic administration of WAY-181187 with haloperidol produced antidepressant- and anxiolytic-like activities. SB-742457 did not provide full benefits in terms of improvement of haloperidol-induced adverse mood effects. However, the administration of SB-742457 with risperidone triggered its anxiolytic-like activity. Both 5-HT6R ligands evoked no changes in haloperidol-induced effects on BDNF level. WAY-181187 induced repression of the BDNF gene while SB-742457 increased its expression in both structures. 5-HT6R ligands, when combined with risperidone, did not change BDNF protein level and increased gene expression in the hippocampus, while they elevated BDNF level and potentiated gene expression in the prefrontal cortex.Conclusion: The combined administration of WAY-181187 and haloperidol provided the greatest benefits, which were manifested by antidepressant-like effects and suppression of the anxiogenic-like properties. The combined administration of risperidone with both agonist and antagonist resulted only in an anxiolytic-like effect. It seems that the anxiolytic-like effects induced by haloperidol or risperidone with the addition of 5-HT6R ligands are task-specific. The data on BDNF protein and gene expression did not fully correspond with the behavioral outcomes, and thus it appears that other factors/mechanisms are involved in the observed antidepressant- and/or anxiolytic-like effects.Keywords: schizophrenia, haloperidol, risperidone, 5-HT6 receptor ligands, BDNF, ratsWesołowska ARychtyk JGdula-Argasińska JGórecka KWilczyńska-Zawal NJastrzębska-Więsek MPartyka ADove Medical Pressarticleschizophreniahaloperidolrisperidone5-ht6 receptor ligandsbdnfratsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 2105-2127 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
schizophrenia haloperidol risperidone 5-ht6 receptor ligands bdnf rats Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
schizophrenia haloperidol risperidone 5-ht6 receptor ligands bdnf rats Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wesołowska A Rychtyk J Gdula-Argasińska J Górecka K Wilczyńska-Zawal N Jastrzębska-Więsek M Partyka A Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| description |
Anna Wesołowska,1 Joanna Rychtyk,1 Joanna Gdula-Argasińska,2 Katarzyna Górecka,1 Natalia Wilczyńska-Zawal,1 Magdalena Jastrzębska-Więsek,1 Anna Partyka1 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland; 2Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, PolandCorrespondence: Anna PartykaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, Kraków, 30-688, PolandTel/Fax +48 126 205 654Email annairena.partyka@uj.edu.plBackground: The presence of depressive and anxiety symptoms in patients with schizophrenia may have an important impact on treatment and compliance. Hence, interventions addressing such comorbidity in schizophrenia should be explored. One target may be a serotonergic 5-HT6 receptor (5-HT6R) since its ligands displayed antidepressant- and anxiolytic-like activities in preclinical experiments.Methods: Acute and chronic (21 days) administration of haloperidol or risperidone in combination with a selective 5-HT6R agonist (WAY-181187) or antagonist (SB-742457) to rats was performed for detecting antidepressant- and anxiolytic-like behaviors. In addition, the level of brain-derived neurotrophic factor (BDNF) protein and its gene expression in hippocampus and prefrontal cortex were determined.Results: Both single and chronic administration of WAY-181187 with haloperidol produced antidepressant- and anxiolytic-like activities. SB-742457 did not provide full benefits in terms of improvement of haloperidol-induced adverse mood effects. However, the administration of SB-742457 with risperidone triggered its anxiolytic-like activity. Both 5-HT6R ligands evoked no changes in haloperidol-induced effects on BDNF level. WAY-181187 induced repression of the BDNF gene while SB-742457 increased its expression in both structures. 5-HT6R ligands, when combined with risperidone, did not change BDNF protein level and increased gene expression in the hippocampus, while they elevated BDNF level and potentiated gene expression in the prefrontal cortex.Conclusion: The combined administration of WAY-181187 and haloperidol provided the greatest benefits, which were manifested by antidepressant-like effects and suppression of the anxiogenic-like properties. The combined administration of risperidone with both agonist and antagonist resulted only in an anxiolytic-like effect. It seems that the anxiolytic-like effects induced by haloperidol or risperidone with the addition of 5-HT6R ligands are task-specific. The data on BDNF protein and gene expression did not fully correspond with the behavioral outcomes, and thus it appears that other factors/mechanisms are involved in the observed antidepressant- and/or anxiolytic-like effects.Keywords: schizophrenia, haloperidol, risperidone, 5-HT6 receptor ligands, BDNF, rats |
| format |
article |
| author |
Wesołowska A Rychtyk J Gdula-Argasińska J Górecka K Wilczyńska-Zawal N Jastrzębska-Więsek M Partyka A |
| author_facet |
Wesołowska A Rychtyk J Gdula-Argasińska J Górecka K Wilczyńska-Zawal N Jastrzębska-Więsek M Partyka A |
| author_sort |
Wesołowska A |
| title |
Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| title_short |
Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| title_full |
Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| title_fullStr |
Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| title_full_unstemmed |
Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats |
| title_sort |
effect of 5-ht6 receptor ligands combined with haloperidol or risperidone on antidepressant-/anxiolytic-like behavior and bdnf regulation in hippocampus and prefrontal cortex of rats |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/0698d54e34d4401ab7e961b71676cadf |
| work_keys_str_mv |
AT wesołowskaa effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT rychtykj effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT gdulaargasinskaj effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT goreckak effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT wilczynskazawaln effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT jastrzebskawiesekm effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats AT partykaa effectof5ht6receptorligandscombinedwithhaloperidolorrisperidoneonantidepressantanxiolyticlikebehaviorandbdnfregulationinhippocampusandprefrontalcortexofrats |
| _version_ |
1718379447772512256 |